8 research outputs found
3-D T1 relaxation time measurements in an equine model of subtle post-traumatic osteoarthritis using MB-SWIFT
No full textThis dataset contains Key analysis and plotting scripts, data, and sample images. 3-D T1 relaxation time measurements in equine model of post-traumatic osteoarthritis using MB-SWIFT Journal of Orthopaedic Research | DOI: 10.1002/jor.25629 Swetha Pala (1), Nina Hänninen (1,2), Ali Mohammadi(1), Mohammadhossein Ebrahimi (1,2), Nikae C.R. te Moller(3), Harold Brommer(3), P. René van Weeren (3), Janne T.A. Mäkelä (1), Rami K. Korhonen (1), Isaac O. Afara(1), Juha Töyräs (1,4,5), Santtu Mikkonen (1), Mikko J. Nissi (1*), Olli Nykänen (1,2) 1Department of Applied Physics, University of Eastern Finland 2Research Unit of Medical Imaging, Physics and Technology, University of Oulu 3Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University 4Science Service Center, Kuopio University Hospital, Kuopio, Finland 5School of Information Technology and Electrical Engineering, The University of Queensland *Corresponding author Mikko J. Nissi Department of Technical Physics University of Eastern Finland, Kuopio Finland POB 1627 70211 Kuopio [email protected] +358-50-5955517 Running title: ‘3D T1 of mild PTOA using MB-SWIFT’ Keywords: Quantitative MRI, T1 relaxation, equine model,post-traumatic osteoarthritis, proteoglycan content. Included folders and files are: - Article_figures: all figures published in the manuscript (.svg format) - Data: Raw MRI data files per flip angle (phase & magnitude images) from 28 samples and corresponding fitted T1 maps within respective folders. SPSS structured data files used for statistical analysis. - Matlab scripts: Matlab functions used for data processing and T1 computation, aedes plugins, and data analysis with subfolders and files: - aedes_plugins: plugins for aedes (http://aedes.uef.fi) and scripts for calculation of surface visualisations from relaxation time maps and auto-segmented mesh. - Data processing and T1 computation: Scripts for non-linear 3D T1 fitting. - Analysis: Key scripts used for analysis and plotting. - README.txt: this file describing the contents of the dataset. See more info in separate readme files included in sub-folders. (Swetha Pala, 31May 2023
Communal diversity of Endophytic fungi among various Medicinal Plants
No full text<p><strong>Abstract:</strong> Medicinal plants have been traditionally utilized by marginalized communities for curing a broad range of health conditions. In traditional medicine, a range of well-being issues are addressed by utilizing different tissues from medicinal plants. . Each tissue of these medicinal plants produces variety of secondary metabolites with pharmacological effects. These tissues also harboures many endophytes that stimulates the growth and secondary metabolite production by the plants. The medicinal plants namely Andrographis paniculata, Abutilon indicum, Ipomea lacunose Aeglemarmelos,Ocimum,Withania sominifera ,Tinospora are some of the important medicinal plants with a variety of applications like anticancer properties, immunomodulatory effects, anti-hepatotoxic qualities, anti-atherosclerotic attributes, anti-hyperglycemic potential, and antioxidative activities, anti-hyperglycemic potential, anti-convulsant activity and larvicidal activities These medicinal plants have demonstrated the existence of promising endophytic strains with potential applications for enhancing crop growth and addressing oxidative stress. This study aims to uncover the diversity of endophytes residing within these medicinal plants</p><p><strong>Keywords:</strong> Endophytic fungi, Medicinal plants, bioactive compounds, Microbial diversity.</p><p><strong>Title:</strong> Communal diversity of Endophytic fungi among various Medicinal Plants</p><p><strong>Author:</strong> Swetha Vallabhaneni, Lakshmi Sharvani K.S, Guru Prasad C, Siva Prasad B.V, Durbaka V R Prasad, Vijaya Lakshmi D</p><p><strong>International Journal of Life Sciences Research</strong></p><p><strong>ISSN 2348-313X (Print), ISSN 2348-3148 (online)</strong></p><p><strong>Vol. 11, Issue 4, October 2023 - December 2023</strong></p><p><strong>Page No: 9-19</strong></p><p><strong>Research Publish Journals</strong></p><p><strong>Website: www.researchpublish.com</strong></p><p><strong>Published Date: 18-November-2023</strong></p><p><strong>DOI: </strong><a href="https://doi.org/10.5281/zenodo.10153311"><strong>https://doi.org/10.5281/zenodo.10153311</strong></a></p><p><strong>Paper Download Link (Source)</strong></p><p><a href="https://www.researchpublish.com/papers/communal-diversity-of-endophytic-fungi-among-various-medicinal-plants"><strong>https://www.researchpublish.com/papers/communal-diversity-of-endophytic-fungi-among-various-medicinal-plants</strong></a></p>
“Keeping it steady”: Anaesthetic challenges in insulinoma surgery
No full textInsulinoma is a tumor of the pancreas that secretes excessive insulin, causing recurrent hypoglycemia. The median presentation age of 47 years and a mild female preponderance. Most cases are benign, with only 10% showing malignant potential. A typical presentation involves Whipple's triad, which includes symptomatic hypoglycemia, fasting blood glucose below 50 mg/dL, and immediate relief of symptoms after glucose administration. This case report discusses the perioperative anaesthetic management of a 54-year-old patient with insulinoma who underwent laparoscopic enucleation. A comprehensive approach involving preoperative blood glucose optimization through medications and dietary adjustments, vigilant intraoperative monitoring with timely dextrose infusion during tumor manipulation, and careful postoperative control of rebound hyperglycemia using insulin infusion is essential for improved outcomes in these patients. The primary treatment is surgical enucleation, but managing perioperative glycemic fluctuations presents significant challenges for anesthesiologists
СУЧАСНИЙ СТАН СТВОРЕННЯ, ВИРОБНИЦТВА ТА ДОСЛІДЖЕННЯ ТАБЛЕТОВАНИХ ЛІКАРСЬКИХ ПРЕПАРАТІВ Повідомлення 20. Характеристика процесу створення та дослідження гастроретентивних систем доставки лікарських речовин.
No full textMODERN STATE OF CREATION, PRODUCTION AND RESEARCH OF DRUGSM.B. Demchuk, N.P. Darzuli, T.A. Hroshovyi, S.V. Demchuk1TernopilStateMedicalUniversityby I.Ya. Horbachevsky1JSC “Ternopharm”Notice 20. The characteristic of process of creating and research of gastroretentive drug delivery system.Summary: the literature on the benefits of the use and technological aspects of obtaining gastroretentive drug delivery system, such as floating, high density (sinking), mucoadhesive and magnetic systems, super porous hydrogel and matrix systems are summarized.Keywords: gastroretentive drug delivery system, gastrointestinal tract, intragastric floating systems.Introduction. Oral administration is the most convenient and preferred means of any drug delivery to the systematic circulation. Dosage forms with a prolonged gastric residence time, i.e. gastro retentive dosage forms (GRDFs), will provide us with new and important therapeutic options. GRDFs extend significantly the period of time over which the drug may be released. Thus, they not only prolong dosing intervals, but also increase patient compliance beyond the level of existing controlled release dosage forms. Gastroretentive drug delivery is an approach to prolong gastric residence time, thereby targeting site-specific drug release in the upper gastrointestinal tract for local or systemic effects. Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility for drugs that are less soluble in a high pH environment. It has applications also for local drug delivery to the stomach and proximal small intestine. The most important parameters which has impact on the gastric retention time of oral dosage forms include: density, size and shape of the dosage form, food intake and its nature, caloric content and frequency of intake, posture, gender, age, sex, sleep, body mass index, physical activity and diseased states of the individual (e.g. chronic disease, diabetes etc.) and administration of drugs with impact on gastrointestinal transit time.Various attempts have been made to retain the dosage form in the stomach as a way of increasing the retention time. These attempts include introducing floating dosage forms (gas-generating systems and swelling or expanding systems), mucoadhesive systems, high-density systems, modified shape systems, gastric- emptying delaying devices and co administration of gastric emptying delaying drugs.Floating drug delivery systems have a bulk density less than gastric fluids and so remain buoyant in the stomach without affecting gastric emptying rate for a prolonged period of time. While the system is floating on the gastric contents, the drug is released slowly at the desired rate from the system. Floating drug delivery systems can be divided into non effervescent and gasgenerating (effervescent) system.High density (sinking) or non- floating drug delivery systems have the density that must exceed density of normal stomach content (~ 1.004 gm/cm3). These formulations are prepared by coating drug on a heavy core or mixed with inert materials such as iron powder, barium sulphate, zinc oxide and titanium oxide etc.Bioadhesive drug delivery systems (BDDS) are used as a delivery device within the lumen to enhance drug absorption in a site specific manner. This approach involves the use of bioadhesive polymers, which can adhere to the epithelial surface in the stomach. Materials commonly used for bioadhesion are polyacrylic acid, chitosan, cholestyramine, sodium alginate, hydroxypropyl methylcellulose, sucralfate, tragacanth, dextrin, polyethylene glycol and polylactic acids etc.Super porous hydrogel systems. In this approach to improve gastric retention time super porous hydrogels of average pore size >100 micro miter, swell to equilibrium size within a minute due to rapid water uptake by capillary wetting through numerous interconnected open pores.Magnetic systems. This approach to enhance the gastric retention time is based on the simple principle that the dosage form contains a small internal magnet, and a magnet placed on the abdomen over the position of the stomach.Conclusions. The basic requirements and approaches to the development of gastroretentive drug delivery systems and examples to obtain tablets that can be kept for a long time in the stomach are considered.References1. Garg R. Progress in sontrolled gastroretentive delivery systems / R Garg, GD Gupta // Tropical Journal of Pharmaceutical Research. – 2008. - №7(3). – R.1055-1066. 2. Review on gastroretentive drug delivery system / A. Badoni I, A. Ojha, G. Gnanarajan et al. // The pharma innovation. – 2012. - Vol.1, № 8. – R.32-42.3. AReview on gastroretentive drug delivery system / Pranav Joshi, Priyank Patel,Hiren Modi et al. // International Journal of Pharmaceutical Science and Bioscientific Research. – 2012. – Vol. 2, Issue 3. – P.123-128.4. Streubel A. Drug delivery to the upper small intestine window using gastroretentive technologies / Streubel A, Siepmann J, Bodmeier R. // Curr Opin Pharmacol. – 2006. - №6. – R.501-508.5. Floating drug delivery systems: A review / Arrora S, Ali J, Khar RK et al. // AAPS Pharm Sci Tech. – 2005. - №6(3). – R. 372-390.6. Nasa P. Floating systems: a novel approach towards gastroretentive drug delivery systems / Praveen Nasa, Sheefali Mahant, Deepika Sharma // International Journal of Pharmacy and Pharmaceutical Sciences. – 2010. - Vol 2, №3. – R. 2-7.7. Gastroretentive drug delivery systems: A review of formulation approaches / P. Rathee, M. Jain, S. Rathee et al. // The pharma innovation. – 2012. - Vol.1, № 8. – R.79 - 107.8. Swetha S. A Comprehensive review on gastroretentive drug delivery systems / Sandina Swetha, Ravi Teja Allena, DV. Gowda // International Journal of Research in Pharmaceutical and Biomedical Sciences. – 2012. - Vol. 3 (3). – R. 1285-1293.9. Amit Kumar Nayak Gastroretentive drug delivery systems: a review / Amit Kumar Nayak, Ruma Maji, Biswarup Das // Asian Journal of Pharmaceutical and Clinical Research. - 2010. - Vol.3, Iss. 1. – R.2-10.10. Jaimini M. Formulation and evaluation of famotidine floating tablets / Jaimini M., Rana AC., Tanwar YS. // Current drug delivery. – 2007. - №4. –R.51-55.11. Development, in-vitro evaluation & study of effect of hardness on buoyancy time of gastro retentive floating tablets of famotidine / Akbari B.V., Dholakiya R.B., Shiyani B.G. et al. // Journal of Pharmacy Research. – 2009. - №2(10). – R.1579-1583. 12. Abeda Aqther Formulation and in-vitro evaluation of ornidazole gastroretentive tablets by using low density swellable polymers / Abeda Aqther, B. Pragati kumar, Peer Basha // Indian Journal of Research in Pharmacy and Biotechnology. – 2013. - № 1(5). - P.597-601.13. Formulation and evaluation of gastroretentive tablets of furosemide (Evaluation based on drug release kinetics and factorial designs) / Deepak Jain, Sofiya Verma, Shashi Bharti Shukla et al. // J. Chem. Pharm. Res. – 2010.- №2(4). – R.935-978.14. Rakesh Pahwa Floating granules of metformin hydrochloride: preparation and optimization using factorial design / Rakesh Pahwa, Seema Bisht, Vipin Kumar // Bulletin of Pharmaceutical Research. - 2012. - №1. – R.42.15. Rakesh Pahwa Formulation and characterization of glipizide loaded floating microspheres / Rakesh Pahwa, Nidhi Saini, Neeta, Vipin Kumar // Bulletin of Pharmaceutical Research. - 2012. - №1. – R.44.16. Formulation and evaluation of sitagliptin phosphate gastroretentive tablets / Krishna Keerthi Brahmandam, Sasikanth Kothamasu, Anitha Makineni et al. // Carib.j.SciTech. – 2014.- Vol.2. – P. 270-281.17. Preparation and evaluation of gastroretentive floating tablets of mebendazole / Krunal Patel, Biswajit Biswal., Nabin Karna et al. // International Journal of Current Pharmaceutical Research. – 2011. - Vol 3, Issue 1. – P.63-65.18. Omray L. K. Design of gastroretentive drug delivery system of diltiazem hydrochloride / L. K. Omray // International Journal of Pharma Sciences and Research. – 2014. - Vol 5., №2. – R.16-19.19. Ghugarkar P. Advances in gastroretentive drug delivery system: a review / Ghugarkar P. // World Journal of Pharmacy and Pharmaceutical Sciences. – 2015. – Vol. 4, Issue 07. – P.512-521.20. Ashok Ch. M. Development and in vitro evaluation of gastroretentive high density tablet of propafenone hcl / Chordiya Mayur Ashok, Senthil Kumaran K, Gangurde Hemant Hiraman // Asian J Pharmaceut Res Health Care. – 2013. – Vol.2, №5. – P.89-99.21. Saikh Mahammed Athar Alli Developing gastro retentive tablets: prospective planning / Saikh Mahammed Athar Alli // Inter. J. of Pharmacotherapy. – 2014. - №4(1). – R.36-42.22. Gastroretentive drug delivery system of a lipid lowering agent / D. Krishnarajan, N. Senthil Kumar, R.Yadav // International Current Pharmaceutical Journal. – 2013. - №2(9). – R.152-155.23. Ankit Anand Kharia Formulation and evaluation of gastroretentive drug delivery system of acyclovir as mucoadhesive nanoparticles / Ankit Anand Kharia, Akhlesh Kumar Singhai // International Journal of PharmTech Research. – 2013. - №5(4). – R. 1538-1545. 24. Jivani R. R. Design and development of a self correcting monolithic gastroretentive tablet of baclofen / R.R. Jivani, Ch.N. Patel, N.P. Jivani // Sci Pharm. – 2009. - №77. – R. 651–667.25. Makarova O.H. Vybor polymerov dlya sozdanyya matrychnoy platformy hastroretentyvnykh tabletok / O.H. Makarova, V.F. Turetskova // Fundamental research. – 2013. - №1. – S.458-462.26. Hromova L.Y. Hastroretentyvnye tabletky atsyklovyra na osnove synerhychesky vzaymodeystvuyushchykh polysakharydov / L.Y. Hromova, D. Khoykhman, Y. Sela // Khymyko-farm. zhurn. – 2007. – T.41, №12. – S. 34-36.27. Rezhym dostupu: http://www.prnewswire.com/news-releases/endorex-presents-drug-delivery-and-cancer-product-updates-at-european-conference-74154997.htm
СУЧАСНИЙ СТАН СТВОРЕННЯ, ВИРОБНИЦТВА ТА ДОСЛІДЖЕННЯ ТАБЛЕТОВАНИХ ЛІКАРСЬКИХ ПРЕПАРАТІВ Повідомлення 20. Характеристика процесу створення та дослідження гастроретентивних систем доставки лікарських речовин.
No full textMODERN STATE OF CREATION, PRODUCTION AND RESEARCH OF DRUGSM.B. Demchuk, N.P. Darzuli, T.A. Hroshovyi, S.V. Demchuk1TernopilStateMedicalUniversityby I.Ya. Horbachevsky1JSC “Ternopharm”Notice 20. The characteristic of process of creating and research of gastroretentive drug delivery system.Summary: the literature on the benefits of the use and technological aspects of obtaining gastroretentive drug delivery system, such as floating, high density (sinking), mucoadhesive and magnetic systems, super porous hydrogel and matrix systems are summarized.Keywords: gastroretentive drug delivery system, gastrointestinal tract, intragastric floating systems.Introduction. Oral administration is the most convenient and preferred means of any drug delivery to the systematic circulation. Dosage forms with a prolonged gastric residence time, i.e. gastro retentive dosage forms (GRDFs), will provide us with new and important therapeutic options. GRDFs extend significantly the period of time over which the drug may be released. Thus, they not only prolong dosing intervals, but also increase patient compliance beyond the level of existing controlled release dosage forms. Gastroretentive drug delivery is an approach to prolong gastric residence time, thereby targeting site-specific drug release in the upper gastrointestinal tract for local or systemic effects. Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility for drugs that are less soluble in a high pH environment. It has applications also for local drug delivery to the stomach and proximal small intestine. The most important parameters which has impact on the gastric retention time of oral dosage forms include: density, size and shape of the dosage form, food intake and its nature, caloric content and frequency of intake, posture, gender, age, sex, sleep, body mass index, physical activity and diseased states of the individual (e.g. chronic disease, diabetes etc.) and administration of drugs with impact on gastrointestinal transit time.Various attempts have been made to retain the dosage form in the stomach as a way of increasing the retention time. These attempts include introducing floating dosage forms (gas-generating systems and swelling or expanding systems), mucoadhesive systems, high-density systems, modified shape systems, gastric- emptying delaying devices and co administration of gastric emptying delaying drugs.Floating drug delivery systems have a bulk density less than gastric fluids and so remain buoyant in the stomach without affecting gastric emptying rate for a prolonged period of time. While the system is floating on the gastric contents, the drug is released slowly at the desired rate from the system. Floating drug delivery systems can be divided into non effervescent and gasgenerating (effervescent) system.High density (sinking) or non- floating drug delivery systems have the density that must exceed density of normal stomach content (~ 1.004 gm/cm3). These formulations are prepared by coating drug on a heavy core or mixed with inert materials such as iron powder, barium sulphate, zinc oxide and titanium oxide etc.Bioadhesive drug delivery systems (BDDS) are used as a delivery device within the lumen to enhance drug absorption in a site specific manner. This approach involves the use of bioadhesive polymers, which can adhere to the epithelial surface in the stomach. Materials commonly used for bioadhesion are polyacrylic acid, chitosan, cholestyramine, sodium alginate, hydroxypropyl methylcellulose, sucralfate, tragacanth, dextrin, polyethylene glycol and polylactic acids etc.Super porous hydrogel systems. In this approach to improve gastric retention time super porous hydrogels of average pore size >100 micro miter, swell to equilibrium size within a minute due to rapid water uptake by capillary wetting through numerous interconnected open pores.Magnetic systems. This approach to enhance the gastric retention time is based on the simple principle that the dosage form contains a small internal magnet, and a magnet placed on the abdomen over the position of the stomach.Conclusions. The basic requirements and approaches to the development of gastroretentive drug delivery systems and examples to obtain tablets that can be kept for a long time in the stomach are considered.References1. Garg R. Progress in sontrolled gastroretentive delivery systems / R Garg, GD Gupta // Tropical Journal of Pharmaceutical Research. – 2008. - №7(3). – R.1055-1066. 2. Review on gastroretentive drug delivery system / A. Badoni I, A. Ojha, G. Gnanarajan et al. // The pharma innovation. – 2012. - Vol.1, № 8. – R.32-42.3. AReview on gastroretentive drug delivery system / Pranav Joshi, Priyank Patel,Hiren Modi et al. // International Journal of Pharmaceutical Science and Bioscientific Research. – 2012. – Vol. 2, Issue 3. – P.123-128.4. Streubel A. Drug delivery to the upper small intestine window using gastroretentive technologies / Streubel A, Siepmann J, Bodmeier R. // Curr Opin Pharmacol. – 2006. - №6. – R.501-508.5. Floating drug delivery systems: A review / Arrora S, Ali J, Khar RK et al. // AAPS Pharm Sci Tech. – 2005. - №6(3). – R. 372-390.6. Nasa P. Floating systems: a novel approach towards gastroretentive drug delivery systems / Praveen Nasa, Sheefali Mahant, Deepika Sharma // International Journal of Pharmacy and Pharmaceutical Sciences. – 2010. - Vol 2, №3. – R. 2-7.7. Gastroretentive drug delivery systems: A review of formulation approaches / P. Rathee, M. Jain, S. Rathee et al. // The pharma innovation. – 2012. - Vol.1, № 8. – R.79 - 107.8. Swetha S. A Comprehensive review on gastroretentive drug delivery systems / Sandina Swetha, Ravi Teja Allena, DV. Gowda // International Journal of Research in Pharmaceutical and Biomedical Sciences. – 2012. - Vol. 3 (3). – R. 1285-1293.9. Amit Kumar Nayak Gastroretentive drug delivery systems: a review / Amit Kumar Nayak, Ruma Maji, Biswarup Das // Asian Journal of Pharmaceutical and Clinical Research. - 2010. - Vol.3, Iss. 1. – R.2-10.10. Jaimini M. Formulation and evaluation of famotidine floating tablets / Jaimini M., Rana AC., Tanwar YS. // Current drug delivery. – 2007. - №4. –R.51-55.11. Development, in-vitro evaluation & study of effect of hardness on buoyancy time of gastro retentive floating tablets of famotidine / Akbari B.V., Dholakiya R.B., Shiyani B.G. et al. // Journal of Pharmacy Research. – 2009. - №2(10). – R.1579-1583. 12. Abeda Aqther Formulation and in-vitro evaluation of ornidazole gastroretentive tablets by using low density swellable polymers / Abeda Aqther, B. Pragati kumar, Peer Basha // Indian Journal of Research in Pharmacy and Biotechnology. – 2013. - № 1(5). - P.597-601.13. Formulation and evaluation of gastroretentive tablets of furosemide (Evaluation based on drug release kinetics and factorial designs) / Deepak Jain, Sofiya Verma, Shashi Bharti Shukla et al. // J. Chem. Pharm. Res. – 2010.- №2(4). – R.935-978.14. Rakesh Pahwa Floating granules of metformin hydrochloride: preparation and optimization using factorial design / Rakesh Pahwa, Seema Bisht, Vipin Kumar // Bulletin of Pharmaceutical Research. - 2012. - №1. – R.42.15. Rakesh Pahwa Formulation and characterization of glipizide loaded floating microspheres / Rakesh Pahwa, Nidhi Saini, Neeta, Vipin Kumar // Bulletin of Pharmaceutical Research. - 2012. - №1. – R.44.16. Formulation and evaluation of sitagliptin phosphate gastroretentive tablets / Krishna Keerthi Brahmandam, Sasikanth Kothamasu, Anitha Makineni et al. // Carib.j.SciTech. – 2014.- Vol.2. – P. 270-281.17. Preparation and evaluation of gastroretentive floating tablets of mebendazole / Krunal Patel, Biswajit Biswal., Nabin Karna et al. // International Journal of Current Pharmaceutical Research. – 2011. - Vol 3, Issue 1. – P.63-65.18. Omray L. K. Design of gastroretentive drug delivery system of diltiazem hydrochloride / L. K. Omray // International Journal of Pharma Sciences and Research. – 2014. - Vol 5., №2. – R.16-19.19. Ghugarkar P. Advances in gastroretentive drug delivery system: a review / Ghugarkar P. // World Journal of Pharmacy and Pharmaceutical Sciences. – 2015. – Vol. 4, Issue 07. – P.512-521.20. Ashok Ch. M. Development and in vitro evaluation of gastroretentive high density tablet of propafenone hcl / Chordiya Mayur Ashok, Senthil Kumaran K, Gangurde Hemant Hiraman // Asian J Pharmaceut Res Health Care. – 2013. – Vol.2, №5. – P.89-99.21. Saikh Mahammed Athar Alli Developing gastro retentive tablets: prospective planning / Saikh Mahammed Athar Alli // Inter. J. of Pharmacotherapy. – 2014. - №4(1). – R.36-42.22. Gastroretentive drug delivery system of a lipid lowering agent / D. Krishnarajan, N. Senthil Kumar, R.Yadav // International Current Pharmaceutical Journal. – 2013. - №2(9). – R.152-155.23. Ankit Anand Kharia Formulation and evaluation of gastroretentive drug delivery system of acyclovir as mucoadhesive nanoparticles / Ankit Anand Kharia, Akhlesh Kumar Singhai // International Journal of PharmTech Research. – 2013. - №5(4). – R. 1538-1545. 24. Jivani R. R. Design and development of a self correcting monolithic gastroretentive tablet of baclofen / R.R. Jivani, Ch.N. Patel, N.P. Jivani // Sci Pharm. – 2009. - №77. – R. 651–667.25. Makarova O.H. Vybor polymerov dlya sozdanyya matrychnoy platformy hastroretentyvnykh tabletok / O.H. Makarova, V.F. Turetskova // Fundamental research. – 2013. - №1. – S.458-462.26. Hromova L.Y. Hastroretentyvnye tabletky atsyklovyra na osnove synerhychesky vzaymodeystvuyushchykh polysakharydov / L.Y. Hromova, D. Khoykhman, Y. Sela // Khymyko-farm. zhurn. – 2007. – T.41, №12. – S. 34-36.27. Rezhym dostupu: http://www.prnewswire.com/news-releases/endorex-presents-drug-delivery-and-cancer-product-updates-at-european-conference-74154997.htm
Control of TGFβ signalling by ubiquitination independent function of E3 ubiquitin ligase TRIP12
No full textInternational audienceTransforming growth factor β (TGFβ) pathway is a master regulator of cell proliferation, differentiation, and death. Deregulation of TGFβ signalling is well established in several human diseases including autoimmune disorders and cancer. Thus, understanding molecular pathways governing TGFβ signalling may help better understand the underlying causes of some of those conditions. Here, we show that a HECT domain E3 ubiquitin ligase TRIP12 controls TGFβ signalling in multiple models. Interestingly, TRIP12 control of TGFβ signalling is completely independent of its E3 ubiquitin ligase activity. Instead, TRIP12 recruits SMURF2 to SMAD4, which is most likely responsible for inhibitory monoubiquitination of SMAD4, since SMAD4 monoubiquitination and its interaction with SMURF2 were dramatically downregulated in TRIP12-/- cells. Additionally, genetic inhibition of TRIP12 in human and murine cells leads to robust activation of TGFβ signalling which was rescued by re-introducing wildtype TRIP12 or a catalytically inactive C1959A mutant. Importantly, TRIP12 control of TGFβ signalling is evolutionary conserved. Indeed, genetic inhibition of Drosophila TRIP12 orthologue, ctrip, in gut leads to a reduced number of intestinal stem cells which was compensated by the increase in differentiated enteroendocrine cells. These effects were completely normalised in Drosophila strain where ctrip was co-inhibited together with Drosophila SMAD4 orthologue, Medea. Similarly, in murine 3D intestinal organoids, CRISPR/Cas9 mediated genetic targeting of Trip12 enhances TGFβ mediated proliferation arrest and cell death. Finally, CRISPR/Cas9 mediated genetic targeting of TRIP12 in MDA-MB-231 breast cancer cells enhances the TGFβ induced migratory capacity of these cells which was rescued to the wildtype level by re-introducing wildtype TRIP12. Our work establishes TRIP12 as an evolutionary conserved modulator of TGFβ signalling in health and disease. © 2023. The Author(s)
Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia
No full textX-linked recessive deficiency of TLR7, a MyD88- and IRAK-4-dependent endosomal ssRNA sensor, impairs SARS-CoV-2 recognition and type I IFN production in plasmacytoid dendritic cells (pDCs), thereby underlying hypoxemic COVID-19 pneumonia with high penetrance. We report 22 unvaccinated patients with autosomal recessive MyD88 or IRAK-4 deficiency infected with SARS-CoV-2 (mean age: 10.9 yr; 2 mo to 24 yr), originating from 17 kindreds from eight countries on three continents. 16 patients were hospitalized: six with moderate, four with severe, and six with critical pneumonia, one of whom died. The risk of hypoxemic pneumonia increased with age. The risk of invasive mechanical ventilation was also much greater than in age-matched controls from the general population (OR: 74.7, 95% CI: 26.8-207.8, P < 0.001). The patients' susceptibility to SARS-CoV-2 can be attributed to impaired TLR7-dependent type I IFN production by pDCs, which do not sense SARS-CoV-2 correctly. Patients with inherited MyD88 or IRAK-4 deficiency were long thought to be selectively vulnerable to pyogenic bacteria, but also have a high risk of hypoxemic COVID-19 pneumonia.sponsorship: We thank the patients and their families for placing their trust in us. We warmly thank A. Dominguez-Acosta, P. Santana-Falcon, E. Rodriguez-Gonzalez, and M.E. Rosales-Bordon for technical assistance, and Y. Nemirovskaya, M. Woollett, D. Liu, S. Boucherit, C. Rivalain, M. Chrabieh and L. Lorenzo for administrative assistance. We are indebted to the "Biobanc de l'Hospital Infantil Sant Joan de Deu per a la Investigacio" for sample and data procurement and "Kids Corona Platform" Hospital Sant Joan de Deu, Barcelona. We would like to thank the members of the International IPF Genetics Consortium (https://github.com/genomicsITER/PFgenetics) for granting access to the genome-wide association studies summary data in the study across five cohorts, and to J.M. Aznar for providing data about mutations in RTEL1 in Spanish patients with IEI. We thank Erin Williams for organizing the logistics of patient samples and whole-exome sequencing. The graphical abstract was created with BioRender.com. The study was funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, PI16/00759, PI18/00223, PI19/00208, PI20/00876, and PI21/00211), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER), the Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FIISC19/43 and FIISC22/27), Grupo DISA (OA18/017 and OA22/035), Fundacion MAPFRE Guanarteme (OA21/131), Cabildo Insular de Tenerife (CGIEU0000219140 and "Apuestas cientificas del ITER para colaborar en la lucha contra la COVID-19"), a 2022 Convocatoria de Beques de Recerca IRSJD-Carmen de Torres 2022 (2022AR-IRSJD-CdTorres), CERCA Programme/Generalitat de Catalunya, the Else Kroener-Fresenius Stiftung (EKFS, 2017_A110), the German Federal Ministry of Education and Research (01GM1910C), the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the Horizon Europe Framework Programme of the European Union under Grant Agreement no. 101057100. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. (Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation|COV20_01333, Spanish Ministry of Science and Innovation|COV20_01334, Spanish Ministry of Science and Innovation|PI16/00759, Spanish Ministry of Science and Innovation|PI18/00223, Spanish Ministry of Science and Innovation|PI19/00208, Spanish Ministry of Science and Innovation|PI20/00876, Spanish Ministry of Science and Innovation|PI21/00211, Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias|RTC-2017-6471-1, Grupo DISA|FIISC19/43, Grupo DISA|FIISC22/27, Fundacion MAPFRE Guanarteme|OA18/017, Fundacion MAPFRE Guanarteme|OA22/035, Cabildo Insular de Tenerife|OA21/131, 2022 Convocatoria de Beques de Recerca IRSJD-Carmen de Torres 2022|CGIEU0000219140, CERCA Programme/Generalitat de Catalunya|2022AR-IRSJD-CdTorres, Else Kroener-Fresenius Stiftung (EKFS), German Federal Ministry of Education and Research|2017_A110, Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health|01GM1910C, Horizon Europe Framework Programme of the European Union, 101057100, National Institute of Allergy and Infectious Diseases|R01AI163029, National Institute of Allergy and Infectious Diseases|R01AI088364, National Institute of Allergy and Infectious Diseases|ZIAAI001265, National Institute of Allergy and Infectious Diseases|ZIAAI001270)status: Publishe
Concordance in the appendix location between ultrasound and surgery findings in children from march to june 2021
No full textilustraciones, gráficas, tablasDescripción: La apendicitis aguda sigue siendo una de las principales causas de intervención quirúrgica en niños, y considerando la ausencia de bibliografía entre la concordancia de la localización del apéndice por ecografía y cirugía; se plantea, a través de este trabajo, realizar desde la radiología un aporte a la literatura médica disponible y al cirujano en el planeamiento previo del abordaje quirúrgico, en función de la localización particular del apéndice en cada paciente. Objetivo: Determinar el rendimiento de la ecografía en la localización del apéndice, al compararlo con los hallazgos de localización quirúrgicos; en niños de la Fundación Hospital Pediátrico la Misericordia, intervenidos de apendicectomía, durante el tiempo comprendido entre marzo a junio de 2021. Metodología: Estudio de corte transversal analítico retrospectivo, entre marzo a junio 2021, en el que se identificaron 154 pacientes pediátricos intervenidos de apendicectomía, con ecografía intrahospitalaria, y diagnóstico anatomopatológico de apendicitis; en la Fundación Hospital de la Misericordia de la ciudad de Bogotá D.C. Estos datos fueron verificados a través del programa Hiruko y los programas de historia clínica del hospital. Se aparearon con una relación 1:1 las localizaciones de la siguiente manera: por ecografía, la localización retrocecal, corresponde a la localización retrocecal en cirugía. La posición pélvica en ecografía, es pélvica en cirugía y la localización preileal, postileal y subcecal en ecografía, corresponde a fosa iliaca derecha en cirugía. En una base de datos de Excel se recolectaron datos demográficos, para conocer factores como la edad, peso, talla, IMC, la patología del apéndice, el tiempo de evolución y las localizaciones intraoperatorias y ecográficas. Posteriormente, se realizó un análisis inferencial descriptivo con métodos gráficos como distribuciones de frecuencias, medidas numéricas de posición, de tendencia central o de dispersión, mediana y diferencia de medianas, para relacionar variables radiológicas con los hallazgos quirúrgicos y determinar así los objetivos descritos en el estudio. Finalmente se emplearon análisis de concordancia entre la localización ecográfica del apéndice y la localización hallada en cirugía a través del índice Kappa. Se realizó un análisis estadístico de correspondencia a través del programa SPSS, así como el coeficiente de correlación de Pearson, para las variables estandarizadas, y el coeficiente Chi cuadrado, con el fin de establecer la asociación y correlación de datos entre sí. Resultados: El 55.19 % son hombres y el 44.81% de la muestra son mujeres, siendo ellos los que más acudieron al hospital con apendicitis. La distribución de frecuencias de edad y las medidas descriptivas oscilaron en su mayoría entre los 10 y 12 años. La media es de 10.7 años y la mediana es de 10 años. La media para la variable peso es de 42 kg y la mediana es de 40 kg. Ambas variables están muy cerca, indicativo de que la distribución es simétrica. En cuanto a la localización en ecografía: el 39% corresponde a localización pélvica, 5,84% a retrocecal, 13,64% a subcecal,11,69% a preileal, 1,3% a postileal, 1,9% a otras y en 40.91% de los casos no se observa el apéndice. El índice de concordancia kappa para la localización en fosa iliaca derecha y localización pélvica fue mediano, de 0.3254 y 0.2688, respectivamente, y para la posición retrocecal fue insignificante de 0.1833. La sensibilidad como proporción de verdaderos positivos, correctamente localizados por la ecografía es del 38 %. La especificidad como la proporción de individuos correctamente localizados, dado que el apéndice no se hallaba en esa ubicación, es del 88%. El análisis estadístico de correspondencia, arrojó que cada una de las localizaciones, bien sea por ecografía o cirugía, influyen de manera similar entre sí, excepto en el caso de la localización retrocecal, donde se observan alejados entre sí. Chi2 es estadísticamente significativa en todas las posiciones: en la posición retrocecal (0.005), pélvica (0.001) y fosa iliaca (0.000). En todas las localizaciones, se rechaza la hipótesis nula (P<0.05), por lo que se concluye que hay una relación entre las variables categóricas de ecografía y cirugía. Conclusión: la ecografía no es la prueba de elección para la localización del apéndice dada su baja sensibilidad para este escenario; sin embargo, dada su alta especificidad, una vez el radiólogo la localiza, permite definir bien cual no es su posición en ecografía. (Texto tomado de la fuente).Outline: Acute appendicitis continues to be one of the main causes of surgical intervention in children and considering the absence of literature, between the concordance of the location of the appendix by ultrasound and surgery; Through this work, it is proposed to make a contribution from radiology to the available medical literature and to the surgeon in the previous planning of the surgical approach, depending on the particular location of the appendix in each patient. Objective: To determine the performance of ultrasound in the location of the appendix, when compared with surgical location findings in children of the La Misericordia Children's Hospital Foundation, undergoing appendectomy surgery, during the period from March to June 2021. Methodology: Retrospective descriptive cross-sectional study, between March and June 2021, in which 154 pediatric patients operated on appendectomy, with in-hospital ultrasound, and anatomopathological diagnosis of appendicitis were identified at the Hospital de la Misericordia Foundation in the city of Bogotá D.C. These data were verified through the Hiruko program and the hospital's medical history programs. The locations were paired with a 1:1 ratio as follows: by ultrasound, the retrocecal location corresponds to the retrocecal location in surgery. The pelvic position in ultrasound, is pelvic in surgery and the preileal, postileal and subcecal location in ultrasound, corresponds to the right iliac fossa in surgery. In an Excel database, demographic data were collected to know factors such as age, weight, height, BMI, appendix pathology, time of evolution and intraoperative and ultrasound locations. Subsequently, an analytical descriptive inferential analysis was performed with graphic methods such as frequency distributions, numerical measures of position, central tendency or dispersion, median and median difference, to relate radiological variables with the surgical findings and thus determine the objectives described in the study. Finally, concordance analysis was used between the ultrasound location of the appendix and the location found in surgery through the Kappa index. A statistical analysis of correspondence was performed through the SPSS program, as well as the Pearson correlation coefficient, for the standardized variables and the Chi square coefficient, in order to establish the association and correlation of data with each other. Results: The 55.19 % are men and 44.81 % of the sample are women, being men the ones most attending the hospital with appendicitis. The age frequency distribution and descriptive measures ranged mostly from 10 to 12 years. The median is 10.7 years and the median is 10 years. The mean for the variable weight is 42 kg and the median is 40 kg. Both variables are very close, indicating that the distribution is symmetrical. Regarding the location in ultrasound: 39% corresponds to pelvic location, 5.84% to retrocecal, 13.64% to subcecal, 11.69% to preileal, 1.3% to postileal, 1.9% to others and in 40.91% of cases the appendix is not observed.The kappa concordance index for the location in the right iliac fossa and pelvic location was medium, of 0.3254 and 0.2688, respectively, and for the retrocecal position it was insignificant of 0.1833. The sensitivity as a proportion of true positives, correctly located by ultrasound is 38 %. The specificity as the proportion of correctly located individuals, since the appendix was not in that location, is 88 %. The statistical analysis of correspondence showed that each of the locations, either by ultrasound or surgery, influence in a similar way with each other, except in the case of the retrocecal location, where they are observed far from each other. Chi2 is statistically significant in all positions: in the retrocecal position (0.005), pelvic (0.001) and iliac fossa (0.000). In all locations, the null hypothesis (P<0.05) is rejected, so it is concluded that there is a relationship between the categorical variables of ultrasound and surgery. Conclusion: ultrasound is not the test of choice for the location of the appendix given its low sensitivity for this scenario; however, because of its high specificity, once the radiologist localizes it, we can define in a good way which is not the appendix location. In addition, when the appendix is located on ultrasound, there is agreement with surgery: median in right iliac fossa and pelvic positions and insignificant in the retrocecal position.Although this agreement is low, it is clinically important, because other prospective studies could give more statistical power, so then, this work tool can help in a more individualized surgery according to the appendix location.Incluye anexosEspecialidades MédicasEspecialista en Radiología Pediátric
